Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Sapparapu G, Fernandez E, Kose N, Bin Cao , Fox JM, Bombardi RG, Zhao H, Nelson CA, Bryan AL, Barnes T, Davidson E, Mysorekar IU, Fremont DH, Doranz BJ, Diamond MS, Crowe JE (2016) Nature 540: 443-447 Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress. Fox JM, Long F, Edeling MA, Lin H, van Duijl-Richter MKS, Fong RH, Kahle KM, Smit JM, Jin J, Simmons G, Doranz BJ, Crowe JE, Fremont DH, Rossmann MG, Diamond MS (2015) Cell 163: 1095-1107 A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease. Graham RL, Becker MM, Eckerle LD, Bolles M, Denison MR, Baric RS (2012) Nat Med 18: 1820-6 HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design. Flyak AI, Ruiz S, Colbert MD, Luong T, Crowe JE, Bailey JR, Bjorkman PJ (2018) Cell Host Microbe 24: 703-716.e3 A plasmid-based reverse genetics system for animal double-stranded RNA viruses. Kobayashi T, Antar AA, Boehme KW, Danthi P, Eby EA, Guglielmi KM, Holm GH, Johnson EM, Maginnis MS, Naik S, Skelton WB, Wetzel JD, Wilson GJ, Chappell JD, Dermody TS (2007) Cell Host Microbe 1: 147-57 Evaluation of candidate vaccine approaches for MERS-CoV. Wang L, Shi W, Joyce MG, Modjarrad K, Zhang Y, Leung K, Lees CR, Zhou T, Yassine HM, Kanekiyo M, Yang ZY, Chen X, Becker MM, Freeman M, Vogel L, Johnson JC, Olinger G, Todd JP, Bagci U, Solomon J, Mollura DJ, Hensley L, Jahrling P, Denison MR, Rao SS, Subbarao K, Kwong PD, Mascola JR, Kong WP, Graham BS (2015) Nat Commun 6: 7712 Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms. Mankowski MC, Kinchen VJ, Wasilewski LN, Flyak AI, Ray SC, Crowe JE, Bailey JR (2018) Proc Natl Acad Sci U S A 115: E82-E91 Hepatitis C virus NS3/NS4A DNA vaccine induces multiepitope T cell responses in rhesus macaques mimicking human immune responses [corrected]. Lang Kuhs KA, Ginsberg AA, Yan J, Wiseman RW, Khan AS, Sardesai NY, O'Connor DH, Weiner DB (2012) Mol Ther 20: 669-78 Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and nonhuman primates. Crowe JE, Bui PT, Firestone CY, Connors M, Elkins WR, Chanock RM, Murphy BR (1996) J Infect Dis 173: 829-39 Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. Wright PF, Karron RA, Belshe RB, Thompson J, Crowe JE, Boyce TG, Halburnt LL, Reed GW, Whitehead SS, Anderson EL, Wittek AE, Casey R, Eichelberger M, Thumar B, Randolph VB, Udem SA, Chanock RM, Murphy BR (2000) J Infect Dis 182: 1331-42 Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. Karron RA, Wright PF, Crowe JE, Clements-Mann ML, Thompson J, Makhene M, Casey R, Murphy BR (1997) J Infect Dis 176: 1428-36 A mouse model for Betacoronavirus subgroup 2c using a bat coronavirus strain HKU5 variant. Agnihothram S, Yount BL, Donaldson EF, Huynh J, Menachery VD, Gralinski LE, Graham RL, Becker MM, Tomar S, Scobey TD, Osswald HL, Whitmore A, Gopal R, Ghosh AK, Mesecar A, Zambon M, Heise M, Denison MR, Baric RS (2014) mBio 5: e00047-14 Infant vaccinations and risk of childhood acute lymphoblastic leukaemia in the USA. Groves FD, Gridley G, Wacholder S, Shu XO, Robison LL, Neglia JP, Linet MS (1999) Br J Cancer 81: 175-8 Virology in the 21st century. Enquist LW, Editors of the Journal of Virology (2009) J Virol 83: 5296-308 Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine. Kimble JB, Malherbe DC, Meyer M, Gunn BM, Karim MM, Ilinykh PA, Iampietro M, Mohamed KS, Negi S, Gilchuk P, Huang K, Wolf YI, Braun W, Crowe JE, Alter G, Bukreyev A (2019) J Virol 93: Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination. Nivarthi UK, Kose N, Sapparapu G, Widman D, Gallichotte E, Pfaff JM, Doranz BJ, Weiskopf D, Sette A, Durbin AP, Whitehead SS, Baric R, Crowe JE, de Silva AM (2017) J Virol 91: The temperature-sensitive (ts) phenotype of a cold-passaged (cp) live attenuated respiratory syncytial virus vaccine candidate, designated cpts530, results from a single amino acid substitution in the L protein. Juhasz K, Whitehead SS, Bui PT, Biggs JM, Crowe JE, Boulanger CA, Collins PL, Murphy BR (1997) J Virol 71: 5814-9 Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity. Whitehead SS, Firestone CY, Karron RA, Crowe JE, Elkins WR, Collins PL, Murphy BR (1999) J Virol 73: 871-7 Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccines. Sakurai H, Williamson RA, Crowe JE, Beeler JA, Poignard P, Bastidas RB, Chanock RM, Burton DR (1999) J Virol 73: 2956-62 Human metapneumovirus fusion protein vaccines that are immunogenic and protective in cotton rats. Cseke G, Wright DW, Tollefson SJ, Johnson JE, Crowe JE, Williams JV (2007) J Virol 81: 698-707 Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus. Kulkarni AB, Collins PL, Bacik I, Yewdell JW, Bennink JR, Crowe JE, Murphy BR (1995) J Virol 69: 1261-4 An alphavirus replicon-based human metapneumovirus vaccine is immunogenic and protective in mice and cotton rats. Mok H, Tollefson SJ, Podsiad AB, Shepherd BE, Polosukhin VV, Johnston RE, Williams JV, Crowe JE (2008) J Virol 82: 11410-8 Immunotherapy for HCV infection: next steps. Lang K, Weiner DB (2008) Expert Rev Vaccines 7: 915-23 Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus. Boyington JC, Joyce MG, Sastry M, Stewart-Jones GB, Chen M, Kong WP, Ngwuta JO, Thomas PV, Tsybovsky Y, Yang Y, Zhang B, Chen L, Druz A, Georgiev IS, Ko K, Zhou T, Mascola JR, Graham BS, Kwong PD (2016) PLoS One 11: e0159709 Human metapneumovirus as a major cause of human respiratory tract disease. Crowe JE (2004) Pediatr Infect Dis J 23: S215-21 Severe acute respiratory syndrome coronavirus pathogenesis, disease and vaccines: an update. Denison MR (2004) Pediatr Infect Dis J 23: S207-14 Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B. Zhan X, Hurwitz JL, Krishnamurthy S, Takimoto T, Boyd K, Scroggs RA, Surman S, Portner A, Slobod KS (2007) Vaccine 25: 8782-93 Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines. Crowe JE (1998) Vaccine 16: 1423-32 Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Crowe JE, Bui PT, London WT, Davis AR, Hung PP, Chanock RM, Murphy BR (1994) Vaccine 12: 691-9 A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Crowe JE, Bui PT, Davis AR, Chanock RM, Murphy BR (1994) Vaccine 12: 783-90 Immunogenicity and efficacy of alphavirus-derived replicon vaccines for respiratory syncytial virus and human metapneumovirus in nonhuman primates. Bates JT, Pickens JA, Schuster JE, Johnson M, Tollefson SJ, Williams JV, Davis NL, Johnston RE, Schultz-Darken N, Slaughter JC, Smith-House F, Crowe JE (2016) Vaccine 34: 950-6 Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development. Crowe JE (1995) Vaccine 13: 415-21 Isolation and characterization of a highly attenuated respiratory syncytial virus (RSV) vaccine candidate by mutagenesis of the incompletely attenuated RSV A2 ts-1 NG-1 mutant virus. Hsu KH, Crowe JE, Lubeck MD, Davis AR, Hung PP, Chanock RM, Murphy BR (1995) Vaccine 13: 509-15 Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Crowe JE, Bui PT, Siber GR, Elkins WR, Chanock RM, Murphy BR (1995) Vaccine 13: 847-55 A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Crowe JE, Collins PL, London WT, Chanock RM, Murphy BR (1993) Vaccine 11: 1395-404 Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate. Firestone CY, Whitehead SS, Collins PL, Murphy BR, Crowe JE (1996) Virology 225: 419-22 A cold-passaged, attenuated strain of human respiratory syncytial virus contains mutations in the F and L genes. Connors M, Crowe JE, Firestone CY, Murphy BR, Collins PL (1995) Virology 208: 478-84 The live attenuated subgroup B respiratory syncytial virus vaccine candidate RSV 2B33F is attenuated and immunogenic in chimpanzees, but exhibits partial loss of the ts phenotype following replication in vivo. Crowe JE, Randolph V, Murphy BR (1999) Virus Res 59: 13-22 An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Murphy BR, Hall SL, Kulkarni AB, Crowe JE, Collins PL, Connors M, Karron RA, Chanock RM (1994) Virus Res 32: 13-36 Update on active specific immunotherapy with melanoma vaccines. Conforti AM, Ollila DW, Kelley MC, Gammon G, Morton DL (1997) J Surg Oncol 66: 55-64
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.